Servier Archives

News and Trends 3 Nov 2022

Servier and OSE Immunotherapeutics complete enrollment in Sjögren’s syndrome trial

Servier and French biotech company OSE Immunotherapeutics SA have completed patient enrollment in a phase 2a clinical trial evaluating the efficacy and safety of monoclonal antibody OSE-127/S95011 in primary Sjögren’s…

November 3, 2022 - 2 minutesmins - By Jim Cornall

In Depth 11 Oct 2021

A Cure for Cancer? How CAR-T Cell Therapy is Revolutionizing Oncology

CAR-T therapy has been hailed as a cure for cancer, but what really is this ‘miraculous technology’ and what can we actually expect from it? The field of immuno-oncology is…

October 11, 2021 - 10 minutesmins - By Clara Rodríguez Fernández

More News! 19 Sep 2018

This Liver Model Made With 4D Bioprinting Could Improve Drug Toxicity Testing

Poietis has partnered with the pharma company Servier to develop a 4D bioprinted liver model that could predict liver toxicity of drugs better than current methods. Liver toxicity testing is…

September 19, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

servier transgene car t cells viral vector

News and Trends 29 Jun 2017

Servier Recruits Viral Vector Expert to Step Up its CAR-T Technology

Transgene will help Servier develop new methods based on viral vectors to improve the precision of genetic modifications and the production of CAR-T cells. The French pharma Servier decided to…

June 29, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

In Depth 25 Apr 2017

How Biotech is Mastering Multiple Sclerosis: A Review

With last month’s FDA approval, Ocrevus (ocrelizumab), became the first drug for primary-progressive multiple sclerosis. Roche may be the first, but others in the biotech community are also working hard…

April 25, 2017 - 7 minutesmins - By Diana Kwon

News and Trends 6 Jan 2017

Servier offers up to €1.7B for Dual Cancer Checkpoint Inhibitors

Servier has signed a deal that could give it access to up to eight bispecific drug candidates with immuno-oncology applications from Pieris Pharmaceuticals. Servier, one of France's biggest pharma companies,…

January 6, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

Best in Biotech 22 Dec 2016

The 10 Biggest Clinical Success Stories of 2016 in European Biotech

What are the most impressive advances in medical biotechnology this year? From cancer to peanut allergy, here's a list of the best success stories of 2016. Biotech is becoming a…

December 22, 2016 - 5 minutesmins - By Clara Rodríguez Fernández

News and Trends 23 Jun 2016

Cellectis gets paid for a first Milestone, Investors are pleased

After successfully 'saving' two babies with terminal-stage acute Leukemia, Cellectis finally treated the first patient in its Phase I trial. A major milestone that could confirm the potential of its…

June 23, 2016 - 2 minutesmins - By Jerome Topsent

servier lonsurf colorectal cancer trifluridine tipiracil

News and Trends 28 Apr 2016

EU approves Combo-Drug for Metastatic Colorectal Cancer

Servier sees one of its combo-drug (trifluridine/tipiracil) approved by the European Commission, after showing a 2 month improvement in overall survival for metastatic Colorectal cancer. The largest private Pharma from France, Servier…

April 28, 2016 - 2 minutesmins - By Denise Neves Gameiro

geneuro euronext multiple sclerosis biotech

News and Trends 16 Apr 2016

First Euronext Biotech IPO of 2016 is Swiss, and for Multiple Sclerosis!

We last wrote about GeNeuro in January, when they announced the launch of an IPO for their Multiple Sclerosis phase IIb trial. Now, as of yesterday they are listed on…

April 16, 2016 - 2 minutesmins - By Dani Bancroft

cellectis ucart leukemia cancer gmp manufacturing ucart19 ucart123 allogeneic universal 2015 financial results

News and Trends 16 Mar 2016

How Good was 2015 for the French Universal CAR-T Biotech?

Cellectis (France) has now released its financial results for 2015. What happened and what the prospects for 2016 and long-term? It was a really packed year for Cellectis, the French…

March 16, 2016 - 3 minutesmins - By Denise Neves Gameiro

leukemia ucart19 cellectis cancer cart trial UK

News and Trends 4 Jan 2016

Cellectis Full-Steam Ahead with UCART19 Trial for Leukemia in the UK

So it begins...dubbed the 'Miracle Cure' for Blood Cancer, UCART19 is now set to begin its journey to Human trials in the UK. Just 2 days before Christmas, the French…

January 4, 2016 - 2 minutesmins - By Dani Bancroft

frits ahlefeldt cellectis servier pfizer ucart leukemia1

News and Trends 19 Nov 2015

Why has the Universal CAR-T Treatment For Leukemia Hooked TWO Big Pharmas at Once?

French Servier and Pfizer have already had independent partnerships with Cellectis on various R&D areas. But now the two have signed a joint partnership on Cellectis's leading product UCART19 for…

November 19, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 29 Oct 2015

Cellectis UCART Milestone: One step closer to a Universal CAR-T Therapy for Blood Cancer

Cellectis is a leader in immuno-oncology CAR-T therapies from France, which might revolutionise cancer treatments. Now, the next step in the CAR-T campaign is to step away from personalised (autologous)…

October 29, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 18 Sep 2015

Servier to revolutionize Diabetes treatment thanks to Intarcia’s successful Phase III

Treatment of diabetes hasn't changed so much since the development of first human insulin by Genentech. But Boston-based Intarcia (a partner of Servier and one of the 9 billion-dollar Biotech…

September 18, 2015 - 3 minutesmins - By Philip Hemme

News and Trends 15 Jul 2015

How Servier saved Cellectis, the French CAR-T Miracle

Cellectis, the €1bn CAR-T company, just announced it reached a significant milestone in its collaboration with Servier. Surprisingly, early 2014, Cellectis and its 300 employees were only three months away from…

July 15, 2015 - 5 minutesmins - By Philip Hemme

News and Trends 15 Dec 2014

Will there be a New Merck-Serono?

GeNeuro SA has signed a unique partnership with Servier. The French pharmaceutical giant have bought an option for €38M on the marketing rights outside the United States and Japan for…

December 15, 2014 - 2 minutesmins - By Julie Lellouche

Intarcia Platform Technology deal Servier

News and Trends 15 Nov 2014

Why do Servier bets one Billion euros on Revolutionary Diabetes Drugs Delivery Device?

The French company Servier wants to invest one billion euros by a partnering with the American company Intarcia regarding their subcutaneous implant for diabetes. This is a breakthrough micropump, the first…

November 15, 2014 - 2 minutesmins - By Julie Lellouche

Report: new Frontiers in Vaccinology

Listen to our podcast

View all sectors A-Z

Power your event with partnering to deliver attendee ROI. Learn more!

View all companies A-Z

Partner with industry leaders working on sustainable materials R&D

View all countries A-Z

Report: The European Biotech Startup Ecosystem

Subcribe to our newsletter

Learn more about Inova, the leading platform for biopharma partnering